Click on the tab to search across Lilly for additional information

The Healthcare Professional's connection to Lilly product and condition information

Search across Lilly Select a search category, select a topic from the pull-down menu, add optional keyword(s), then click on the search button

Product:

Condition:

Byetta^®
(exenatide) injection Capastat^® Sulfate
(capreomycin for injection, USP) Cialis^®
(tadalafil) Cymbalta^®
(duloxetine hydrochloride) Evista^®
(raloxifene HCl) Forteo^®
(teriparatide [rDNA origin] injection) Lilly Glucagon
(glucagon by injection [rDNA origin]) Humalog^®
(insulin lispro injection [rDNA origin]) Humalog^® Mix50/50™
(50% insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin]) Humalog^® Mix75/25™
(75% insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin]) Humulin^®
(human insulin [rDNA origin]) Humatrope^®
(somatropin [rDNA origin] for injection) Prozac^®
(fluoxetine hydrochloride) Quinidine Gluconate Injection, USP
ReoPro^®
(abciximab) Seromycin^®
(cycloserine capsules, USP) Symbyax^®
(olanzapine and fluoxetine hydrochloride) Xigris^®
(drotrecogin alfa [activated]) Zyprexa^®
(olanzapine)

Acute Bipolar Mania Adult Growth Hormone Deficiency Bipolar Depression Diabetes Diabetic Peripheral Neuropathic Pain (DPNP) Erectile Dysfunction Idiopathic Short Stature (ISS) Major Depressive Disorder (MDD) Osteoporosis Pediatric Growth Hormone Deficiency Schizophrenia Severe Sepsis Turner Syndrome

Click on the tab to search across Lilly for additional information

Cymbalta® (duloxetine HCl) is approved for the treatment of depression and generalized anxiety disorder, and for the management of diabetic peripheral neuropathic pain and fibromyalgia.

Product Information

Cymbalta and MDD

Multidimensional Aspects of Depression

Major depressive disorder (MDD) has a broad range of symptoms, including depressed mood, loss of interest, feelings of guilt, lack of energy, decreased concentration, changes in appetite, sleep or psychomotor activity, and recurrent thoughts of death or suicidality. Other associated symptoms may also include anxiety, bodily aches and pains, and irritability.¹ Treating MDD can be complex. Patients may present with a broad range of symptoms.

Cymbalta Demonstrated Broad Efficacy, Safety and Tolerability, and Once-daily Dosing in MDD

Broad efficacy: Cymbalta demonstrated an impact on a broad range of symptoms, rapid improvement from core emotional symptoms as early as week 1^2a, and delayed time to relapse over 6 months for patients with MDD^2a-e
Safety and tolerability: Learn about treatment-emergent adverse events associated with Cymbalta and MDD³
Simplicity: Cymbalta offers simple once daily dosing³

References:

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth edition, Text Revision; Washington, DC: American Psychiatric Association, 2000.
Data on file, Lilly Research Laboratories: CYM20090505C, b. CYM20090505A, c. CYM20090505D, d. CYM20090506A, e. CYM20060101A.
Cymbalta full Prescribing Information, 2009.

Formulary Access Finder

Cymbalta has been added to the Anthem Blue Cross Blue Shield National Preferred Formulary.

Get more information about the formulary access for Cymbalta. Download PDF files of insurance providers covering Cymbalta in your state.

Register to Receive Information From Cymbalta

Keep up-to-date on the latest developments with Cymbalta. Sign up now for our periodic emails.